Recent Finacing
Recent Raise
Grey Wolf Therapeutics is a clinical‑stage UK biotech developing small‑molecule ERAP1/ERAP2 modulators to generate neoantigens and enhance tumour visibility, advancing oral ERAP1 candidate GRWD5769 and MHC I‑directed biologics.
